{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-049411","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.197278+00:00","generated_at":"2026-05-21T05:14:52.848496+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"confidence":"high","headline":"Outlook Therapeutics Q2 FY2025 net loss $46.4M; cash $7.6M; PDUFA Aug 27","bullets":["Net loss $46.4M ($1.50/share) vs $114.3M ($8.01) YoY; adjusted net loss $12.5M ($0.40) vs $22.1M ($1.55).","Cash and equivalents $7.6M as of March 31, 2025; no revenue (pre-commercial stage).","LYTENAVA commercial launch in Germany and UK planned for Q2 CY2025.","FDA PDUFA goal date August 27, 2025 for ONS-5010 (bevacizumab-vikg) BLA resubmission.","Warrant inducement expenses $33.9M and other non-cash items drove adjusted loss items."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-049411","json":"https://secwatch.observer/filing/0001104659-25-049411.json","markdown":"https://secwatch.observer/filing/0001104659-25-049411.md","text":"https://secwatch.observer/filing/0001104659-25-049411.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/0001104659-25-049411-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000110465925049411/tm2515284d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T05:14:52.848496+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}